首页 | 本学科首页   官方微博 | 高级检索  
检索        

辛伐他汀和非诺贝特对小鼠肝脏载脂蛋白M表达的影响及调控机制
引用本文:杨柳,赵水平,张赛丹,李铁.辛伐他汀和非诺贝特对小鼠肝脏载脂蛋白M表达的影响及调控机制[J].中国医师杂志,2010,12(11):1474-1477.
作者姓名:杨柳  赵水平  张赛丹  李铁
作者单位:1. 中南大学湘雅医院老年病科,长沙,410078
2. 中南大学湘雅二医院心血管内科
3. 中南大学湘雅医院心血管内科
4. 长沙市中心医院心血管内科
摘    要:目的 探讨辛伐他汀和非诺贝特及两者联合对小鼠肝脏载脂蛋白M(apoM)表达的影响及其机制,为防治动脉粥样硬化提供依据.方法 32只C57BL/6N小鼠按数字表法分为四组,对照组:普通饮食喂养;他汀组:辛伐他汀10 mg/(kg·d)]干预;贝特组:非诺贝特100 mg/(kg·d)]干预;联合组:辛伐他汀10 mg/(kg·d)]和非诺贝特100 mg/(kg·d)]干预,4周后分别检测小鼠肝脏apoM mRNA和蛋白、肝细胞核因子-1α(HNF-1α)mRNA、肝X受体-α(LXRα)mRNA的表达.结果 辛伐他汀和非诺贝特均上调apoM mRNA(1.97±0.04;2.02±0.02)和蛋白、HNF-1α mRNA(1.74±0.05;1.71±0.04)的表达,联合组(3.07±0.03;2.57±0.03)升高程度高于他汀组(1.97±0.04;1.74±0.05)和贝特组(2.02±0.02;1.71±0.04)(P<0.05).辛伐他汀下调LXRα mRNA(1.00±0.02)表达(P<0.05),非诺贝特上调LXRα mRNA(2.80±0.04)表达(P<0.05),联合组LXRα mRNA表达(1.56±0.03)与对照组(1.53±0.03)比较差异无统计学意义(P>0.05).结论 辛伐他汀和非诺贝特可上调apoM表达,两者联合疗效更显著;其机制可能与两者调控HNF-1α和LXRα有关.

关 键 词:斯伐他汀/药理学  普鲁脂芬/药理学  载脂蛋白类/代谢/药物作用

Effects and mechanism of simvastatin and fenofibrate on the expression of hepatic apolipoprotein M in mice
YANG Liu,ZHAO Shui-ping,ZHANG Sai-dan,LI Tie.Effects and mechanism of simvastatin and fenofibrate on the expression of hepatic apolipoprotein M in mice[J].Journal of Chinese Physician,2010,12(11):1474-1477.
Authors:YANG Liu  ZHAO Shui-ping  ZHANG Sai-dan  LI Tie
Institution:1.Department of Geriatrics, the Xiang ya Hospital of Central South University, Changsha 410078, China;)
Abstract:Objective To examine the effects and mechanisms of simvastatin and fenofibrate, and combination of the two drugs on the expression of apolipoprotein M (apoM). Methods The male C57BL/6N mice ( n =32) were random divided into four groups, including control group (with no special treatment), statin group (with simvastatin 10mg/( kg · d) for 4 weeks], fibrate group (with fenofibrate 100mg/( kg · d) for 4 weeks] and combination group ( with simvastatin 10mg/( kg· d)] and fenofibrate 100mg/( kg · d) for 4 weeks]. The levels of apoMmRNA and protein, hepatic nuclear factor (HNF-1α)mRNA, liver X receptor-α (LXRα) mRNA in mouse liver were measured. Results Both of simvastatin and fenofibrate can increase the expression of apolipoprotein M ( 1.97 ± 0. 04,2. 02 ± 0. 02 ) and HNF-1αmRNA ( 1.74 ± 0. 05,1.71 ± 0. 04). Combination group obtained more effects than either single agent ( P < 0. 05 ). Simvastatin could decrease the expression of LXRα mRNA ( 1.00 ± 0. 02 ) ( P < 0. 05 ). Fenofibrate could increase the expression of LXRα mRNA(2. 80 ±0. 04) ( P <0. 05). No significant difference in LXRα expression was seen between combination( 1.56 ±0. 03 ) and control group( 1.53 ±0. 03 )( P >0. 05). Conclusions Simvastatin and fenofibrate can increase apoM expression. Treatment with combination of the two drugs is more effective, and the mechanism might be related to the regulation of HNF-1α and LXRα.
Keywords:Simvastatin/PD  Procetofen/PD  Apolipoproteins/ME/DE
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号